The Lupus Market is anticipated to have held a market value of USD 1.48 billion in the year 2017 and is expected to grow at a CAGR of 11.2% during the forecast period.
Lupus is an autoimmune disease in which the immune system produces antibodies that attack the body’s healthy tissue. The antibodies produced by the immune system in lupus cause inflammation, tissue damage, and pain. Majority of the patients affected by lupus are women, and the majority of the people develop lupus between 15 to 45 years of age. The growing prevalence of lupus, ongoing medical advancements in the treatment of systemic lupus erythematosus, rising research and development activities are some factors that are expected to propel the market growth during the assessment period. On the other hand, the factors such as strict government regulation and increasing prices of lupus drugs may hinder the market growth over the assessment period.
Many companies are engaged in the global lupus market. The prominent players in the market are engaged in strategic collaborations, and new product launches to strengthen their market position. For instance, in January 2017, Sanofi and ImmuNext agreed to develop treatments for autoimmune diseases including multiple sclerosis and lupus.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/6636
Some of the prominent players in the global lupus market are Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Eli Lily and Company, and Merck KGaA.
The lupus market segmentation is done on the basis of treatment, end-user, and types.
By treatment, the market includes antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, immunosuppressants, and others.
By end-user, the market divides into diagnostic laboratories, hospitals and clinics, and others.
Lastly, by type, the market comprises cutaneous lupus erythematosus, systemic lupus erythematosus, neonatal lupus, and drug-induced lupus erythematosus. The lupus erythematosus market segment is projected to hold the largest market percentage due to the increasing prevalence of such diseases and the increasing drug development over the years.
Geographically, the Americas is expected to dominate the global market owing to the presence of well-developed healthcare sector, rising demand for better treatment options, growing prevalence of lupus, government initiatives for lupus, and availability of reimbursement. Europe is expected to hold the second largest position in the global lupus market owing to the increasing number of research and development activities and the rising prevalence of lupus in the region. Asia-Pacific region is anticipated to be the fastest growing region owing to the growing prevalence of lupus, continuously growing healthcare sector and increasing regional expansion by prominent market players. The Middle East & Africa has the lowest share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector.
Access Report Details @ https://www.marketresearchfuture.com/reports/lupus-market-6636
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America